Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis OTC Habitrol Taking Private Label Tack

This article was originally published in The Tan Sheet

Executive Summary

Novartis Consumer Health is planning a "major" private label initiative with its newly approved OTC nicotine patches involving Wal-Mart, CVS and Walgreens. The firm intends to later market the product under its original Habitrol name, but the initial focus is in the private label setting. OTC Habitrol was approved Nov. 12.
Advertisement

Related Content

Novartis Tavist ND Loratadine Tablets Carry Geneva’s Marketing Exclusivity
Novartis Tavist ND Loratadine Tablets Carry Geneva’s Marketing Exclusivity
Novartis Tavist ND Loratadine Tablets Carry Geneva’s Marketing Exclusivity
Novartis Habitrol Approval Marks First 3-In-1 Smoking Cessation Kit
Novartis Habitrol Approval Marks First 3-In-1 Smoking Cessation Kit
Smoking Cessation Patch, Gum Prop 65 Warning Federally Preempted - Court
Habitrol Nicotine Patch Three-Year Exclusivity Sought By Novartis
SmithKline Nicorette Mint Spurs Gum Sales 8% In Second Quarter
SmithKline Nicorette Mint Spurs Gum Sales 8% In Second Quarter
TCPI Plans Strategic Alliance For Private Label Nicotine Patch

Topics

Advertisement
UsernamePublicRestriction

Register

PS090591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel